Xeomin vs. Jeuveau: Formulation, Onset, and Trial Comparison

Botulinum neurotoxin type A (BoNT-A) injections are the most frequently performed cosmetic procedure in the United States. While Allergan's Botox (onabotulinumtoxinA) remains the market leader and historical benchmark, the medical-aesthetic landscape has expanded to include several competitive alternatives. Among these, Xeomin (incobotulinumtoxinA) and Jeuveau (prabotulinumtoxinA-xvfs) represent two of the most widely used alternatives.

Although both products utilize the same active botulinum neurotoxin serotype to temporarily relax muscles and smooth dynamic wrinkles, they are manufactured using different processes, resulting in different molecular weights, accessory protein complexes, onset times, and marketing focus. Xeomin is known for its highly purified, "naked" formulation designed to minimize antibody resistance, while Jeuveau is positioned as a high-purity, "aesthetic-only" complex designed to deliver rapid results.

First Screen Answer: Xeomin and Jeuveau are Botox alternatives with a 1:1 dosing ratio, 2-4 day onset, and 3-4 month duration. Xeomin is a purified 'naked' toxin (150 kDa), while Jeuveau is a 900 kDa complex.

This clinical, evidence-first comparison evaluates Xeomin and Jeuveau. We review their FDA regulatory backgrounds, molecular structures, clinical trial data, post-market safety records in the FDA FAERS database, and reconstitution logistics to help providers and patients understand their clinical differences.

---

What are the FDA approvals and BLA histories for Xeomin and Jeuveau?

In the United States, botulinum toxins are regulated as biologics by the FDA's Center for Drug Evaluation and Research (CDER). Unlike small-molecule drugs that go through the New Drug Application (NDA) process, biologics are approved through a Biologics License Application (BLA). This designation reflects that botulinum toxins are complex proteins purified from living bacterial cultures (Clostridium botulinum), meaning that the manufacturing process is integral to the final product's characteristics.

FDA BLA Approval Profile: Xeomin vs. Jeuveau
┌──────────────────────────────────────┬──────────────────────────────────────┐
│ Xeomin (incobotulinumtoxinA)         │ Jeuveau (prabotulinumtoxinA-xvfs)    │
├──────────────────────────────────────┼──────────────────────────────────────┤
│ BLA Number: BLA 125360               │ BLA Number: BLA 761085               │
│ Initial Approval: July 30, 2010      │ Approval Date: February 1, 2019      │
│ Cosmetic Approval: July 20, 2011     │ Indication: Glabellar Lines          │
│ Sponsor: Merz Pharmaceuticals        │ Sponsor: Evolus, Inc.                │
└──────────────────────────────────────┴──────────────────────────────────────┘

Xeomin (incobotulinumtoxinA) BLA History

Xeomin, developed by Merz Pharmaceuticals, was approved under a dual therapeutic and cosmetic pathway.

• BLA Number: BLA 125360
• Initial FDA Approval: July 30, 2010. Xeomin was first approved for the treatment of adult patients with cervical dystonia (involuntary neck muscle contractions) and blepharospasm (involuntary eyelid blinking) who had been previously treated with Botox.
• Aesthetic Approval: July 20, 2011. The FDA approved Xeomin for the temporary improvement in the appearance of moderate to severe glabellar (frown) lines in adult patients.
• Subsequent Expansions: Merz has expanded Xeomin's indications over time. In 2020, it was approved for the treatment of blepharospasm as first-line therapy. In 2024, it received approval for the simultaneous treatment of upper facial lines (including forehead lines, glabellar lines, and lateral canthal lines/crow's feet), representing a broad cosmetic clearance.

Jeuveau (prabotulinumtoxinA-xvfs) BLA History

Jeuveau, developed by Daewoong Pharmaceutical in South Korea and licensed and marketed in the U.S. by Evolus, Inc., represents a unique market entry.

• BLA Number: BLA 761085
• FDA Approval Date: February 1, 2019
• Aesthetic Approval: The FDA approved Jeuveau for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients.
• Strategic Positioning: Unlike other U.S. neurotoxins, Jeuveau was developed and is marketed exclusively for aesthetic indications. Evolus has no therapeutic indications for Jeuveau. This allows the company to focus its marketing and pricing strategies solely on the cosmetic sector, earning it the nickname "Newtox."

---

How do the purification chemistry and molecular structure of Xeomin and Jeuveau differ?

The molecular structure of botulinum toxin products is a key point of differentiation. In its natural state, the active botulinum neurotoxin molecule is bound to a group of non-toxic accessory proteins, forming a large molecular complex.

Botulinum Toxin Structure: 900 kDa Complex vs. 150 kDa Naked Toxin
┌───────────────────────────────────────────────────────────────────┐
│ Jeuveau / Botox (900 kDa Complex)                                 │
│ ┌───────────────────────────────────────────────────────────────┐ │
│ │ Hemagglutinins (HA-17, HA-33, HA-70)                          │ │
│ └───────────────────────────────────────────────────────────────┘ │
│ ┌───────────────────────────────────────────────────────────────┐ │
│ │ Non-Toxic Non-Hemagglutinin (NTNH)                            │ │
│ └───────────────────────────────────────────────────────────────┘ │
│ ┌───────────────────────────────────────────────────────────────┐ │
│ │ Active Core Neurotoxin (150 kDa)                              │ │
│ │   [Heavy Chain (100 kDa) ] ─── [Light Chain (50 kDa) ]        │ │
│ └───────────────────────────────────────────────────────────────┘ │
└───────────────────────────────────────────────────────────────────┘

┌───────────────────────────────────────────────────────────────────┐
│ Xeomin (150 kDa Naked Toxin)                                      │
│ ┌───────────────────────────────────────────────────────────────┐ │
│ │ Active Core Neurotoxin (150 kDa)                              │ │
│ │   [Heavy Chain (100 kDa) ] ─── [Light Chain (50 kDa) ]        │ │
│ └───────────────────────────────────────────────────────────────┘ │
└───────────────────────────────────────────────────────────────────┘

Xeomin: The Purified, "Naked" Toxin

Xeomin's defining clinical feature is its high level of purification.

• Purification Process (XTRACT Technology™): Merz uses a proprietary purification process that strips away all accessory complexing proteins (hemagglutinins and non-toxic non-hemagglutinin proteins) from the active neurotoxin molecule.
• Molecular Weight: This process results in a "naked" neurotoxin consisting solely of the active 150 kDa core botulinum toxin type A molecule. In contrast, standard complexed toxins have a molecular weight of approximately 900 kDa.
• Clinical Significance (Immunogenicity): When a patient is injected with botulinum toxin, the body's immune system can recognize the accessory proteins as foreign antigens and develop neutralizing antibodies against them. Over time, these antibodies can neutralize the active toxin, leading to a loss of treatment effectiveness (secondary treatment failure). By removing these accessory proteins, Xeomin theoretically minimizes the risk of antibody formation, making it a suitable option for long-term users or patients who have developed resistance to other complexed toxins.
• Dosing Conversion: Despite its purified structure, Xeomin maintains a 1:1 dosing ratio with Botox. Clinical trials have demonstrated that 20 units of Xeomin deliver equivalent clinical efficacy and duration to 20 units of Botox.

Jeuveau: The 900 kDa Complexed Toxin

Jeuveau is formulated to be molecularly and structurally equivalent to the U.S. market standard.

• Molecular Weight: Jeuveau is a 900 kDa botulinum neurotoxin type A complex, meaning it preserves the natural accessory proteins surrounding the active 150 kDa core.
• Hi-Pure™ Technology: Evolus utilizes a proprietary manufacturing process called Hi-Pure™ technology. This is a multi-step purification process designed to remove denatured, inactive proteins, ensuring that the final formulation contains only active, highly purified 900 kDa complexes.
• Clinical Significance: The presence of accessory proteins does not affect the active toxin's ability to block acetylcholine release at the neuromuscular junction once it has dissociated. However, it means that Jeuveau has a similar immunogenic profile to other complexed toxins like Botox.
• Dosing Conversion: Like Xeomin, Jeuveau has a 1:1 dosing ratio with Botox. A standard glabellar treatment utilizes 20 units of Jeuveau, delivering equivalent clinical outcomes to 20 units of Botox or Xeomin.

---

What do the clinical trials and onset profiles show?

The efficacy and safety of Xeomin and Jeuveau have been established in multiple clinical trials. While both effectively reduce glabellar line severity, their onset profiles and patient satisfaction metrics show subtle differences.

Xeomin Clinical Trials (NCT00427778 & NCT00822107)

The cosmetic approval of Xeomin was supported by two identical, randomized, double-blind, placebo-controlled, multi-center trials involving 547 patients with moderate to severe glabellar lines.

• Study Design: Patients received either 20 units of Xeomin or a placebo, and were followed for up to 120 days. Efficacy was defined as a 2-grade improvement on a 4-point scale at Day 30, assessed by both the investigator and the patient.
• Efficacy Results:
  • At Day 30, 60% of Xeomin-treated patients achieved the primary success criteria, compared to 0% in the placebo group.
  • Onset of Action: Patients began to notice a reduction in muscle activity within 3 to 7 days, with the maximum effect achieved around Day 30.
  • Duration of Effect: The treatment effect lasted an average of 3 to 4 months before muscle movement returned to baseline.
• Safety Profile: The most common adverse events reported in the trials were headache (5.4%), injection site pain (2.2%), and eyelid ptosis (drooping) in less than 1% of patients.

Jeuveau Clinical Trials (EV-001 & EV-002)

Jeuveau's FDA approval was based on two U.S. Phase III trials (EV-001 and EV-002, NCT02341495 and NCT02341508) involving 654 patients.

• Study Design: Patients were randomized in a 3:1 ratio to receive either 20 units of Jeuveau or a placebo. The primary efficacy endpoint was a 2-grade improvement on the glabellar line scale at Day 30.
• Efficacy Results:
  • At Day 30, 70.4% (EV-001) and 67.5% (EV-002) of Jeuveau-treated patients met the primary efficacy endpoint.
  • Onset of Action: Jeuveau is frequently noted for a rapid onset of action. In clinical trials and real-world studies, many patients reported visible reduction in glabellar lines within 2 to 3 days, with some noticing changes as early as 24 hours post-injection.
  • Duration of Effect: Similar to Xeomin, Jeuveau maintains its clinical effect for 3 to 4 months.
• Safety Profile: The adverse event profile was comparable to Xeomin, with headache (6%) and injection site bruising/pain being the most common temporary reactions. Eyelid ptosis occurred in approximately 1% of subjects.

---

Safety Comparison: openFDA FAERS Adverse Event Analysis

To evaluate post-market safety profiles, we analyzed the FDA's FAERS (FDA Adverse Event Reporting System) database, filtering for reports associated with the brand names Xeomin and Jeuveau.

FAERS Adverse Event Reports: Xeomin vs. Jeuveau
┌──────────────────────────────────────┬──────────────────────┐
│ Brand Name                           │ Adverse Event Reports│
├──────────────────────────────────────┼──────────────────────┤
│ XEOMIN                               │ 6,098                │
├──────────────────────────────────────┼──────────────────────┤
│ JEUVEAU                              │ 3,866                │
└──────────────────────────────────────┴──────────────────────┘
Source: openFDA FAERS Database, summary extract dated 2026-06-10.

Analysis of the FAERS Dataset

1. Report Counts: Xeomin has 6,098 reports in the database, while Jeuveau has 3,866 reports. Xeomin's higher count largely reflects its longer time on market and its substantial therapeutic use (cervical dystonia, blepharospasm, sialorrhea, and spasticity in medically complex patients), not a higher cosmetic-injection risk; Jeuveau is approved for aesthetics only and has been on the market roughly half as long.
2. Top Reported Adverse Events:
   • Headache: The most common reaction reported for both products.
   • Blepharoptosis (Eyelid Ptosis): Caused by the local diffusion of the toxin into the levator palpebrae superioris muscle. This is a technique-dependent complication that typically resolves within 2 to 4 weeks.
   • Injection Site Pain & Bruising: Localized, transient injection reactions.
   • Muscular Weakness: Occasional reports of localized muscle weakness beyond the target injection zone.
3. Black Box Warning: Both Xeomin and Jeuveau carry the class-wide FDA boxed warning regarding the risk of distant spread of toxin effect. This warning notes that the toxin can spread from the injection site to produce symptoms consistent with botulinum toxin effects (such as asthenia, generalized muscle weakness, diplopia, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence, and breathing difficulties), which can be life-threatening. This warning applies to all botulinum toxin products.
4. Database Limitations: FAERS is a passive reporting database. The reports are voluntary and do not prove that the drug caused the event. They also do not reflect the overall safety rate because the total number of patients treated (the denominator) is unknown.

---

Reconstitution, Storage, and Clinical Logistics

For aesthetic injectors, the storage requirements and reconstitution parameters of botulinum toxins are key practical considerations.

Storage Conditions

• Xeomin: One of Xeomin's unique practical advantages is its stability. Because it is highly purified and contains no complexing proteins, it does not require refrigeration prior to reconstitution. Unopened vials can be stored at room temperature (up to 25°C or 77°F) for up to 36 months, simplifying storage logistics. Once reconstituted with saline, it must be stored in a refrigerator (2°C to 8°C) and used within 24 hours.
• Jeuveau: Requires refrigeration at all times. Unopened vials must be stored in a refrigerator at temperatures between 2°C to 8°C (36°F to 46°F). Once reconstituted, it should also be refrigerated and used within 24 hours.

Reconstitution Protocol

Both products are supplied as sterile, vacuum-dried solids in glass vials containing either 50 or 100 units of toxin. They must be reconstituted with sterile, preservative-free 0.9% sodium chloride injection (saline).

• Reconstitution Volume: Injectors typically use 2.5 mL of saline per 100-unit vial, which yields a concentration of 4.0 units per 0.1 mL. This concentration allows for precise dosing and minimizes the volume injected, reducing the risk of local diffusion.

Reconstitution Chart (100 Unit Vial)
┌──────────────────────────────────────┬──────────────────────┐
│ Saline Added (mL)                    │ Dose per 0.1 mL (U)  │
├──────────────────────────────────────┼──────────────────────┤
│ 1.0 mL                               │ 10.0 U               │
├──────────────────────────────────────┼──────────────────────┤
│ 1.5 mL                               │ 6.7 U                │
├──────────────────────────────────────┼──────────────────────┤
│ 2.0 mL                               │ 5.0 U                │
├──────────────────────────────────────┼──────────────────────┤
│ 2.5 mL (Clinical Standard)           │ 4.0 U                │
├──────────────────────────────────────┼──────────────────────┤
│ 3.0 mL                               │ 3.3 U                │
├──────────────────────────────────────┼──────────────────────┤
│ 4.0 mL                               │ 2.5 U                │
├──────────────────────────────────────┼──────────────────────┤
│ 5.0 mL (Microtox/Hyperdilute)        │ 2.0 U                │
└──────────────────────────────────────┴──────────────────────┘

---

Switchability and Dosing Conversions

A common question among patients and providers is whether it is safe to switch between different botulinum toxin brands.

• 1:1 Conversion Ratio: Xeomin, Jeuveau, and Botox share a 1:1 dosing ratio. A patient who receives 20 units of Botox in the glabellar region can be transitioned to 20 units of Xeomin or 20 units of Jeuveau without adjusting the dose. For detail on Xeomin conversions compared to Dysport, see our Dysport vs. Xeomin comparison. For details comparing Jeuveau to Dysport, see our Jeuveau vs. Dysport guide.
• Switching due to Resistance: If a patient has stopped responding to complexed toxins like Botox or Jeuveau due to the development of neutralizing antibodies, switching to Xeomin can be clinically beneficial. Because Xeomin lacks accessory proteins, it does not stimulate the same antibody pathways, occasionally restoring treatment efficacy.
• Switching for Cost/Positioning: Jeuveau is often priced lower than other brands due to its aesthetic-only business model. Providers frequently switch patients to Jeuveau to offer a more competitive price per unit while maintaining the same dosing protocol.

Reversibility and Mitigating Adverse Effects

Unlike hyaluronic acid dermal fillers, which can be dissolved with hyaluronidase, botulinum toxins have no direct pharmacological reversal agent. Once the toxin has bound to the presynaptic nerve terminal and cleaved the SNAP-25 protein, the block on acetylcholine release is complete. The clinical effect will only resolve as the nerve terminal sprouts new axons and regenerates its SNAP-25 proteins, a process that takes 3 to 4 months.

However, certain temporary adverse effects can be managed:

Managing Eyelid Ptosis (Drooping)

If the toxin diffuses into the levator palpebrae superioris muscle, it causes the upper eyelid to droop. This can be treated with:

1. Apraclonidine 0.5% Ophthalmic Drops: Apraclonidine is an alpha-2 adrenergic receptor agonist. When applied to the eye, it stimulates Müller's muscle, a smooth muscle in the upper eyelid. Müller's muscle contracts, lifting the eyelid by approximately 1 to 2 mm, which can temporarily counteract the ptosis until the toxin wears off. The dosage is typically 1 to 2 drops in the affected eye three times daily. It should not be used in patients with narrow-angle glaucoma or those taking MAO inhibitors.
2. Technique Adjustment: To avoid ptosis, injectors must keep injections at least 1 cm superior to the orbital rim and avoid injecting medial to the midpupillary line when treating the lateral corrugator. Additionally, manual pressure can be applied along the supraorbital rim during injection to prevent down-diffusion.

Managing Brow Ptosis (Heavy Brows)

Brow ptosis occurs when the frontalis muscle (the only brow elevator) is over-treated, particularly in the lower portion of the forehead.

1. Prevention: The frontalis muscle must be injected carefully, keeping the injections high (at least 2 cm above the brow) and adjusting the dose based on the patient's age and skin laxity. Injectors should map the patient's muscle movements and identify the line of compensation.
2. Management: Once brow ptosis occurs, there is no direct treatment. The provider must wait for the toxin's effect to weaken. In some cases, injecting a small dose of toxin into the brow depressors (the lateral orbicularis oculi) can provide a subtle lift to compensate for the heavy brow.

Managing Asymmetry and Under-Correction

Unlike over-treatment, under-correction is easy to manage:

1. Two-Week Touch-Up: Patients should be evaluated 14 days after injection, which is when botulinum toxins reach their maximum effect. If asymmetry or residual movement is present, small touch-up doses (e.g., 2 to 4 units) can be injected to refine the result.
2. Documentation: The touch-up dose and exact locations must be recorded in the patient's treatment log to adjust the starting dose for future sessions.

---

Provider Guidance: Dosing and Clinical Selection Framework

The choice between Xeomin and Jeuveau often depends on patient-specific factors, treatment history, and clinical objectives. The table below compares the two products head-to-head.

Clinical Selection Guidelines

1. For the Toxin-Naive Patient Seeking Rapid Results:
   • Recommendation: Jeuveau is highly effective for patients who have an upcoming event and want their treatment to take effect quickly. Its 2-to-3-day onset is faster than Xeomin's 3-to-7-day profile.
2. For the Long-Term User Concerned with Resistance:
   • Recommendation: Xeomin is the logical choice for patients who plan to use neurotoxins long-term or those who show signs of decreased response to other brands. Its "naked" formulation minimizes the risk of antibody resistance.
3. For Practices with Limited Refrigerator Space:
   • Recommendation: Xeomin simplifies clinical storage because unopened vials can be stored at room temperature.
4. For Patients Seeking Cost Value:
   • Recommendation: Jeuveau is often the more cost-effective option due to Evolus's aesthetic-focused pricing strategies.

---

Frequently Asked Questions (FAQs)

Is Xeomin cheaper than Jeuveau?

In most medical spas and dermatology practices, Jeuveau is priced slightly lower than Xeomin. Because Evolus markets Jeuveau exclusively for aesthetic indications, they frequently offer practices volume-based discounts and co-op marketing programs, which practices often pass on to patients. However, the final cost to the patient depends on the practice's pricing structure (e.g., price per unit vs. price per treatment area).

Can I switch between Xeomin and Jeuveau without losing effectiveness?

Yes, because both products share a 1:1 dosing conversion ratio, you can transition between them. However, patients should avoid switching brands too frequently (e.g., changing products at every session), as this can make it difficult for your injector to evaluate your response and adjust your treatment plan.

How many units of Xeomin or Jeuveau are injected for frown lines?

The standard U.S. FDA-approved dose for the treatment of moderate to severe glabellar lines is 20 units for both Xeomin and Jeuveau, distributed across 5 injection sites (4 units per site: 2 in each corrugator muscle and 4 in the procerus muscle). Your injector may adjust this dose based on your individual muscle mass and movement patterns.

Do Xeomin and Jeuveau last as long as Botox?

Yes. Clinical trials and real-world studies show that Xeomin, Jeuveau, and Botox all have an average duration of 3 to 4 months. Individual longevity can vary based on the patient's metabolism, muscle mass, and the dose injected.

---

Sources

• U.S. Food and Drug Administration. "Biologics License Application (BLA) Approval: Xeomin (incobotulinumtoxinA) - BLA 125360." July 30, 2010. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125360
• U.S. Food and Drug Administration. "Biologics License Application (BLA) Approval: JEUVEAU (prabotulinumtoxinA-xvfs) - BLA 761085." February 1, 2019. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761085
• ClinicalTrials.gov. "A Study to Evaluate the Efficacy and Safety of NT 201 (incobotulinumtoxinA) in Glabellar Frown Lines (NCT00822107)." https://clinicaltrials.gov/study/NCT00822107
• ClinicalTrials.gov. "Safety and Efficacy of PrabotulinumtoxinA (Jeuveau) for Glabellar Lines: Phase III Study (NCT02341495)." https://clinicaltrials.gov/study/NCT02341495
• Dressler, D. "Comparing Xeomin and Botox: Clinical Equivalence and Dosing." Journal of Neural Transmission, vol. 125, no. 5, 2018, pp. 761–769. (PMID: 29322301) https://pubmed.ncbi.nlm.nih.gov/29322301/
• Beer, K. R., et al. "Efficacy and Safety of PrabotulinumtoxinA (Jeuveau) for the Treatment of Moderate to Severe Glabellar Lines: Results from Two Phase III Randomized Trials." Dermatologic Surgery, vol. 45, no. 12, 2019, pp. 1681–1693. (PMID: 31385901) https://pubmed.ncbi.nlm.nih.gov/31385901/
• U.S. Food and Drug Administration. openFDA FAERS Adverse Event Database Search Interface (Brand Names: XEOMIN, JEUVEAU). Accessed June 10, 2026. https://open.fda.gov/apis/drug/event/